• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Melasma affects dermis, epidermisin most patients

Article

New York - Melasma is a manifestation of sun damage usually seen in individuals with skin types III, IV, and V, Maritza Perez, M.D., said at the second annual meeting of The Skin and Color Center, St. Luke's-Roosevelt Hospital Center, New York.

Recent Videos
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
Related Content
The Weekly Roundup: July 22-26

The Weekly Roundup: July 22-26

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194

Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194

Article
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

Podcast
Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity

Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity

Article
The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

Article
© 2024 MJH Life Sciences

All rights reserved.